Sionna Therapeutics SION 深 沪
已收盘 05-22 16:00:00 美东时间
41.13
-0.620
-1.49%
华盛通- 最 高43.415
- 今 开41.81
- 成交量 18.26万股
- 最 低 40.81
- 昨 收 41.75
- 总市值 185.70万
- 52周最高 48.445
- 市盈率 静 --
- 换手率 0.40%
- 52周最低 13.33
- 委 比 20.00%
- 总股本 4.52万
- 历史最高 48.445
- 量 比 0.59
- 振 幅 6.24%
- 历史最低 7.255
- 每 手 1
- 风险率 9.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
Stifel Maintains Buy on Sionna Therapeutics, Raises Price Target to $55
Stifel analyst Paul Matteis maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises the price target from $44 to $55.
05-19 00:56
U.S. RESEARCH ROUNDUP-Exxon Mobil, Northrop Grumman, Regeneron Pharmaceuticals
U.S. RESEARCH ROUNDUP-Exxon Mobil, Northrop Grumman, Regeneron Pharmaceuticals May 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Exxon Mobil, Northrop Grumman and Regeneron Pharmaceuticals on Monday. HIGHLIGHTS * Ch
05-18 15:15
Sionna Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Sionna Therapeutics shares are trading lower after the company reported worse-t...
05-12 23:17
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
Sionna Therapeutics Q1 EPS $(0.60) Misses $(0.51) Estimate
Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.51) by 17.65 percent. This is a 3.23 percent increase over losses of $(0.62) per share
05-12 19:10
Sionna Therapeutics Reports First Quarter 2026 Financial Results
Sionna Therapeutics reported the completion of enrollment in its Phase 2a trial for SION-719, an NBD1 stabilizer for cystic fibrosis, with topline data expected in summer 2026. The company also noted progress in its Phase 1 trial for SION-451, with dual combination data anticipated in the same timeframe. Sionna maintained a strong cash position of $289.9 million, supporting operations into 2028.
05-12 11:00
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
Wedbush Initiates Coverage On Sionna Therapeutics with Outperform Rating, Announces Price Target of $53
Wedbush analyst Laura Chico initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Outperform rating and announces Price Target of $53.
05-05 21:24
美股大行评级 | 达美乐比萨惨遭10家大行下调目标价；铿腾电子、艾克尔科技、Relay 、辛普森配件制造、TFI International等获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Intellia Therapeutics"买入"评级，目标价从48美元升至58美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从7美元升至8美元
04-29 10:28
